Cascadian Therapeutics Inc (NASDAQ:CASC) has been given an average recommendation of “Hold” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.00.

Separately, Zacks Investment Research raised shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Monday, November 13th.

Cascadian Therapeutics (NASDAQ CASC) opened at $4.07 on Tuesday. The firm has a market cap of $205.78, a PE ratio of -3.04 and a beta of 2.29. Cascadian Therapeutics has a 12 month low of $3.18 and a 12 month high of $4.97.

Cascadian Therapeutics (NASDAQ:CASC) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same quarter in the previous year, the business posted ($0.09) EPS. analysts predict that Cascadian Therapeutics will post -1.27 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Cascadian Therapeutics by 24.1% during the second quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock worth $6,567,000 after buying an additional 343,838 shares during the period. Dimensional Fund Advisors LP boosted its stake in Cascadian Therapeutics by 423.0% during the third quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock worth $2,094,000 after buying an additional 414,019 shares during the period. State Street Corp lifted its position in shares of Cascadian Therapeutics by 1,113.7% during the second quarter. State Street Corp now owns 411,299 shares of the biopharmaceutical company’s stock worth $1,527,000 after purchasing an additional 377,410 shares in the last quarter. Northern Trust Corp lifted its position in shares of Cascadian Therapeutics by 415.5% during the second quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock worth $1,420,000 after purchasing an additional 308,270 shares in the last quarter. Finally, P.A.W. Capital Corp acquired a new stake in shares of Cascadian Therapeutics during the third quarter worth about $982,000. 80.33% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.watchlistnews.com/cascadian-therapeutics-inc-casc-given-average-rating-of-hold-by-brokerages/1808717.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.